The potential of positron-emission tomography to study anticancer-drug resistance.
Affiliation
Academic Department of Radiation Oncology and Manchester Molecular Imaging Centre, University of Manchester, Christie NHS Trust Hospital, Wilmslow Road, Manchester, M20 4BX, United Kingdom. catharine.west@man.ac.ukIssue Date
2004-06
Metadata
Show full item recordCitation
The potential of positron-emission tomography to study anticancer-drug resistance. 2004, 4 (6):457-69 Nat. Rev. CancerJournal
Nature Reviews. CancerDOI
10.1038/nrc1368PubMed ID
15170448Type
ArticleLanguage
enISSN
1474-175Xae974a485f413a2113503eed53cd6c53
10.1038/nrc1368
Scopus Count
Collections
Related articles
- Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography.
- Authors: Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO
- Issue date: 2003
- Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.
- Authors: Brady F, Luthra SK, Brown GD, Osman S, Aboagye E, Saleem A, Price PM
- Issue date: 2001 Dec
- PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
- Authors: Fredriksson A, Stone-Elander S
- Issue date: 2003
- The applications of positron emission tomography to oncology.
- Authors: Ott RJ
- Issue date: 1991 Mar
- Positron emission tomography: a new investigational area for cancer research.
- Authors: Wells P, Harte RJ, Price P
- Issue date: 1996